



JUNE 18-22, 2018

ADVANCED TB DIAGNOSTICS

“As healthcare workers many times we do not produce science but we ‘consume’ it to give better care to the patients. It was great to see how the brilliant minds in TB world work to improve how to approach the control of this disease.”

– ADVANCED TB DIAGNOSTICS PARTICIPANT

This advanced course will cover advanced topics in TB diagnostics research and implementation, including critical pathway for new TB tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. The course will also cover meta-analysis, mathematical modeling, and cost-effectiveness studies. Panel discussions will cover topics such as value chain for TB diagnostics development, market analyses, market dynamics, target product profiles, and barriers to scale-up of new diagnostics. Participants will include TB survivors, product manufacturers, donors, product development partnerships, policy makers, academics, clinicians, community advocates, public health implementers and National TB Program managers.

COURSE DIRECTOR

Madhukar Pai, MD, PhD

Professor of Epidemiology, McGill University
Director, McGill Global Health Programs
Associate Director, McGill International TB Centre

COURSE FACULTY

Niaz Banaei, MD – Stanford University

Claudia Denkinger, MD, PhD – FIND

Jim Gallarda, Bill & Melinda Gates Foundation

Adithya Cattamanchi, MD – UCSF

David Dowdy, MD, PhD – Johns Hopkins University

Paul K. Drain, MD, MPH, FACP – University of Washington

Nora Engel, PhD – Maastricht University

Jennifer Furin, MD, PhD – Harvard Medical School

Robyn Lee, PhD – Harvard University

Ruvandhi Nathavitharana, MBBS – BIMDC Harvard Medical School

Marco Schito, PhD – The Critical Path Institute

Samuel Schumacher, MSc, PhD – FIND

Karen Steingart, MD, MPH – Cochrane ID Group

Anita Suresh, MBA, MS – FIND

Cesar Ugarte-Gil, MD, PHD – Universidad Peruana Cayetano Heredia

CONTENT

Diagnosis is one of the biggest gaps in the TB cascade of care. We need better tools for TB diagnosis than what we have today and we need high quality diagnostic studies to evaluate new tools, and to develop evidence-based policies on TB diagnostics. We need data on outcomes such as accuracy of diagnostic algorithms (rather than single tests) and their relative contributions to the healthcare system, incremental value of new tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. Translation of policy into impact requires collecting evidence for scale-up, country-level data on cost-effectiveness and feasibility, implementation research, and local decisions on scale-up, delivery and impact assessment. All of these issues will be covered in this week-long, advanced course.

OBJECTIVES

By the end of the course, participants will understand:

- value chain for TB diagnostics development, current pipeline of diagnostics, market dynamics, WHO policies on new diagnostics, and challenges for scale-up
- designs to evaluate impact of new tests on clinical decision-making, therapeutic choices, and patient-important outcomes
- meta-analyses of diagnostic accuracy studies and GRADE approach to diagnostic policies
- principles of implementation research, collecting evidence for scale-up, cost-effectiveness analyses and modeling studies in TB diagnostics

TARGET AUDIENCE

- National TB Program managers and National Reference Lab managers
- Clinicians and nurses
- Researchers, students, trainees, fellows and academics involved in TB diagnostics research
- Product manufacturers
- Funding agencies
- Product development partnerships
- Policy makers and public health implementers
- Community advocates and civil society

ENROLMENT

Maximum of 100 participants.

2018 COURSES To Register: <http://mcgill-idgh.ca/>



McGill

**McGill Summer Institute in
Infectious Diseases and
Global Health**